PTPRC and hepatocellular carcinoma: In both, MASLD (Fig. S5A, not significant) and HCC/NRASG12V/p19Arf-/- mice (Fig. S5H), an increase in CD19+B220+CD138+ PBs was observed, similar to the findings in the HCC/CaMIN mouse model.